Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Sutro Biopharma and keeping the price target at $50.00.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Andres Y. Maldonado has given his Buy rating due to a combination of factors, starting with his view that the market’s sharp negative reaction to the initial STRO-004 data is disproportionate to the actual clinical evidence. He argues that the early dataset, while limited, already shows a favorable safety and pharmacokinetic profile alongside initial responses in several difficult-to-treat solid tumors, supporting the potential of Sutro’s ADC platform.

Maldonado’s rating is based on the belief that the STRO-004 results provide early proof-of-concept that Sutro’s high drug-load, precisely engineered ADCs can translate as expected in humans, with manageable toxicity and dose-proportional exposure. He further highlights the upcoming clinical entry of STRO-006 and the planned IND for STRO-227 as meaningful pipeline catalysts, and therefore maintains his long-term conviction and leaves his price target unchanged at $50, reinforcing the Buy recommendation.

According to TipRanks, Y. Maldonado is a 5-star analyst with an average return of 41.7% and a 58.55% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Verastem, and Monopar Therapeutics Inc.

In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $54.00 price target.